NEW YORK (GenomeWeb) – NeoGenomics announced today its participation as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice, or NCI-MATCH, precision medicine cancer treatment clinical trial.
As a designated sequencing lab for the trial, the Fort Myers, Florida-based company will use its NeoType Discovery Panel to identify patients who may be eligible for treatment of their tumor types at clinical sites participating in NCI-MATCH. The panel assesses 320 cancer-related genes in solid tumors, hematologic malignancies, and advanced sarcomas.